Drug Price Trends for ROSUVASTATIN CALCIUM

Average Pharmacy Cost for ROSUVASTATIN CALCIUM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROSUVASTATIN CALCIUM 40 MG TAB	82009-0020-30	0.09207	EACH	2025-03-19
ROSUVASTATIN CALCIUM 40 MG TAB	82009-0020-10	0.09207	EACH	2025-03-19
ROSUVASTATIN CALCIUM 20 MG TAB	82009-0019-90	0.05912	EACH	2025-03-19
ROSUVASTATIN CALCIUM 20 MG TAB	82009-0019-10	0.05912	EACH	2025-03-19
ROSUVASTATIN CALCIUM 10 MG TAB	82009-0018-90	0.04246	EACH	2025-03-19
ROSUVASTATIN CALCIUM 10 MG TAB	82009-0018-10	0.04246	EACH	2025-03-19

Market Analysis and Price Projections for Rosuvastatin Calcium

Market Overview

The global Rosuvastatin Calcium market is experiencing significant growth, driven by increasing demand for effective cholesterol-lowering medications. Here are the key points to consider:

Market Size and Growth Projections

The Rosuvastatin Calcium market was valued at US$ 548.5 million in 2024 and is projected to reach US$ 694.1 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.0% during the forecast period of 2024-2030[1].

Another projection indicates that the market size was US$ 600.64 million in 2024 and is expected to expand to US$ 940.6 million by 2033, with a CAGR of 5.11% during the period 2025-2033[4].

Market Segmentation

The market is segmented by type, application, and region. The types include purity levels such as 98.0%, 99.0%, and others, while applications include tablets (dispersible and general), capsules, and others[1][3].

Geographically, the market is divided into regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Europe is a significant consumer, accounting for about 34% of global production, followed by China with a market share of 28%[1].

Key Players

The market is dominated by several key players, including MSN Laboratories, Cadila Pharmaceuticals, LGM Pharma, Bal Pharma, Changzhou Pharmaceutical Factory, and others. These companies collectively account for a substantial portion of the market share[1].

Cost-Effectiveness

Rosuvastatin Calcium is noted for its cost-effectiveness compared to other statins like atorvastatin. The average cost per patient treated to European LDL-C goals is significantly lower for rosuvastatin, standing at $130.18 compared to $242.44 for atorvastatin[2].

Market Trends

Increasing Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases globally is a major driver for the Rosuvastatin Calcium market. Approximately 31% of global deaths are attributed to cardiovascular conditions, creating a robust demand for cholesterol-lowering drugs[4].

Growing Generic Drug Penetration

The expiration of key patents has led to the proliferation of generic versions of Rosuvastatin Calcium, which now account for nearly 70% of the total market share. This trend makes affordability a key driver for market expansion[4].

Advanced Manufacturing Technologies

The integration of advanced manufacturing technologies such as continuous processing and precision dosage forms is enhancing product efficiency and patient adherence. This innovation is expected to contribute to the market's sustained growth[4].

E-commerce Distribution

The adoption of e-commerce channels for pharmaceutical distribution has increased by over 20% annually, enabling better accessibility to Rosuvastatin Calcium products, especially in remote areas[4].

Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases: The increasing awareness about preventive healthcare and the high prevalence of cardiovascular diseases drive the demand for Rosuvastatin Calcium[4].
• Expansion in Emerging Markets: Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth potential due to rising healthcare expenditure and improving healthcare infrastructure[4].

Restraints

• Stringent Regulatory Frameworks: Compliance with Good Manufacturing Practices (GMP) and documentation requirements increases costs and delays product launches, impacting market entry for new players[4].

Challenges

• Rising Competition from Generics: The proliferation of generic versions puts pressure on pricing and makes it challenging for branded drug manufacturers to maintain their market position[4].

Regional Outlook

The market exhibits varied growth patterns across different regions:

• North America and Europe: These regions represent mature markets with advanced healthcare systems and high awareness about cardiovascular diseases.
• Asia-Pacific: This region is emerging as a significant growth area due to rising healthcare expenditure and the increasing prevalence of cholesterol-related conditions.
• Middle East & Africa: Market growth is slower but steady, driven by improvements in healthcare access and rising health consciousness[4].

Price Projections and Out-of-Pocket Costs

Market Value Projections

The market is expected to grow from US$ 600.64 million in 2024 to US$ 940.6 million by 2033, indicating a steady increase in market value over the forecast period[4].

Out-of-Pocket Costs

In the U.S., the out-of-pocket cost for rosuvastatin has fluctuated over the years. In 2014, it was around $63, then dropped to between $9 and $10 from 2019 to 2021, and increased to $12.57 in 2022. This trend reflects the impact of generic drug penetration and other market dynamics on patient costs[5].

Key Takeaways

• The Rosuvastatin Calcium market is projected to grow significantly, driven by the increasing prevalence of cardiovascular diseases and the cost-effectiveness of the drug.
• Generic drug penetration is a major factor influencing market dynamics and pricing.
• Advanced manufacturing technologies and e-commerce distribution are enhancing market accessibility and efficiency.
• Emerging markets offer substantial growth opportunities due to rising healthcare expenditure and improving healthcare infrastructure.

FAQs

What is the projected market size of Rosuvastatin Calcium by 2030?

The global Rosuvastatin Calcium market is projected to reach US$ 694.1 million by 2030[1].

Which regions are the largest consumers of Rosuvastatin Calcium?

Europe is the largest consumer, accounting for about 34% of global production, followed by China with a market share of 28%[1].

How does Rosuvastatin Calcium compare to other statins in terms of cost-effectiveness?

Rosuvastatin Calcium is more cost-effective than atorvastatin, with lower costs per patient treated to LDL-C goals[2].

What are the main drivers of the Rosuvastatin Calcium market?

The main drivers include the rising prevalence of cardiovascular diseases, growing generic drug penetration, and expansion in emerging markets[4].

How has the out-of-pocket cost for rosuvastatin changed over the years in the U.S.?

The out-of-pocket cost has fluctuated, dropping significantly from $63 in 2014 to between $9 and $10 from 2019 to 2021, and then increasing to $12.57 in 2022[5].

What are the challenges faced by the Rosuvastatin Calcium market?

The market faces challenges from stringent regulatory frameworks, rising competition from generics, and the need for differentiation through innovation and strategic partnerships[4].

Sources

1. Global Rosuvastatin Calcium Market Insights, Forecast to 2030 - Valuates Reports
2. Rosuvastatin is cost-effective compared with atorvastatin in reaching European LDL-C goals - PubMed
3. Global Rosuvastatin Calcium Drug Market Size, Trends and Forecasts - Market Research Intellect
4. Rosuvastatin Calcium Market Size | Forecast 2025 To 2033 - Global Growth Insights
5. Rosuvastatin out-of-pocket cost U.S. 2004-2022 - Statista